Requests · Texas A&M Veterinary Medical Diagnostic Laboratory
Innovative Next Generation Diagnostics
Priority 1 · one of 2 items in the Texas A&M Veterinary Medical Diagnostic Laboratory's request for 2028-29 · The item begins on page 61 of the request
This is a request, not an appropriation.
What is asked
| 2028 | 2029 | Two years | |
|---|---|---|---|
| All funds | $1,885,000 | $1,885,000 | $3,770,000 |
| Of which general revenue and general revenue-dedicated | $1,885,000 | $1,885,000 | $3,770,000 |
| Positions (full-time equivalents) | 9.0 | 9.0 |
How it would be financed
| Method of financing, as the request prints it | 2028 | 2029 |
|---|---|---|
| 1 General Revenue Fund | $1,885,000 | $1,885,000 |
| Total, as the request prints it | $1,885,000 | $1,885,000 |
Where it would land
The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.
| Strategy | Asked 2028 | Asked 2029 | Positions | Appropriated 2026 | Appropriated 2027 |
|---|---|---|---|---|---|
| 01-01-01 Provide Diagnostic Service and Disease Surveillance | $1,885,000 | $1,885,000 | 9.0 | No strategy matched in the current budget | |
A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.
After 2029
| The agency's estimate | 2030 | 2031 | 2032 | Three years |
|---|---|---|---|---|
| All funds | $1,815,000 | $1,815,000 | $1,815,000 | $5,445,000 |
In the agency's words: Out year cost beyond FY2028 and FY2029 will include salary and personnel costs to continue the program in addition to equipment maintenance cost and funding for free diagnostic testing for unexplained illness or sudden death in Texas animal populations .
The agency's justification
• TVMDL seeks funding to establish next-generation sequencing (NGS) and diagnostic capability in Texas. This is the most critical need for TVMDL and it has been prioritized over other requests to secure Texas' ability to respond to emerging animal diseases before they become economically devastating and widespread throughout animal and wildlife populations. • TVMDL protects Texas' $24B animal agriculture industries and nearly 240,000 related jobs, by detecting animal diseases, many of which also threaten public health. New and evolving disease threats require advanced diagnostic tools to identify pathogens as they mutate, emerge in new hosts, or enter Texas from other states and countries. • Current diagnostics require prior knowledge of the suspected pathogen, limiting the detection of unknown or mutated emerging agents. NGS is pathogen agnostic, enabling identification of any pathogen in a sample, known or unknown, through analyzing pathogens’ DNA and RNA directly from diagnostic samples, reducing the need for multiple targeted tests. • Investing in establishing next-generation diagnostics will position TVMDL as a national leader in early detection of emerging diseases. Peer laboratories in multiple states already use NGS to strengthen disease monitoring and response. • Funding will establish NGS capability at TVMDL, providing rapid testing for beef cattle, dairy, poultry, equine, and other animal species, regardless of the disease agent. • Funding will support 7–9 FTEs of specialized skilled personnel, as well as advanced and ancillary laboratory equipment, bioinformatics software, computational infrastructure, and instrument maintenance. • Funding will support free diagnostic testing for unexplained illness or sudden death in Texas animal populations . It will further enable monitoring of genetic changes in circulating pathogens and accelerate continuous improvement of diagnostic assays to enhance disease detection and emergency outbreak response .
Page 54 90th Regular Session, Agency Submission, Version 1 TIME: 3:46:44PM
External and internal factors
• Texas' 1,254-mile external border and 29 international ports create multiple entry points for animal diseases. Existing pathogens also continually mutate and spread into new species. Texas must be equipped to rapidly detect these threats to protect animal industries, the economy, and public health. • In January 2024, a mysterious disease appeared in Panhandle dairy farms and was identified as highly pathogenic avian influenza affecting cattle for the first time . The outbreak spread to at least 20 states, impacting dairy farms, poultry operations, and farm workers. Estimated losses exceed $1 million per Texas dairy farm. • Current diagnostic tools require knowing which pathogen to look for, so identifying the cause of the outbreak took months and thousands of targeted tests . Next-generation sequencing (NGS) could have identified the cause within days, enabling containment and reducing losses. • The reintroduction of New World screwworm is a major threat with up to $10 billion estimated annual losses in Texas. Current diagnosis relies on visual identification, while NGS would enable assays for rapid and high-throughput detection. • Implementing NGS will strengthen preparedness and prevention for high consequence diseases and support the long- term sustainability of Texas’ animal industries. • Other states already have NGS capabilities. Funding will position Texas as a national leader in early detection of transboundary and emerging diseases .
Results – Major Accomplishments During Next 2 Years: Develop NGS capabilities at TVMDL, recruit essential staff, and establish secure bioinformatics infrastructure.
Consequences of Not Funding: Delayed disease detection increases economic losses and weakens outbreak response, leading to economic damage to animal commodities. Without NGS, Texas will continue to lag, forcing Texas producers and veterinarians to seek advanced diagnostics outside the state and reducing Texas' ability to respond rapidly to emerging animal diseases.
As marked in the request
- Has an information technology part: No
- Costs anticipated after the two budget years: Yes
- Involves contracts over $50,000: No